Chembio Diagnostics

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

CEMI stock is soaring today after the company announced the commercial launch of a rapid Covid-19 test that was met with significant optimism. The post CEMI Stock: One Huge Reason Chembio Is Rocketing Higher Today appeared first on InvestorPlace.

CEMI Stock: One Huge Reason Chembio Is Rocketing Higher Today

Shares of Chembio Diagnostics Inc. skyrocketed 63.8% on record volume in afternoon trading Monday, to pace all gainers listed on major U.S. exchanges, in the wake of the point-of-care diagnostics company's announcement of the commercial launch of its rapid COVID-19/flu test. The stock was on track for the biggest one-day percentage gain since it doubled, on March 12, 2004.

Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test

Nano-X Imaging

Chembio Diagnostics Inc (NASDAQ: CEMI) shares are trading higher by 41% in Monday's pre-market session after the company announced the commercial launch of a test to differentiate between COVID-19 and the Flu. Chembio develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.

Why NNOX Stock And CEMI Stock Are Skyrocketing Today

The stock price of Chembio Diagnostics (NASDAQ: CEMI) increased by over 60% pre-market. This is why it happened.

Chembio Diagnostics Stock Price Increased Over 60% Pre-Market: Why It Happened

In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

Chembio Diagnostics' (CEMI) CEO Rick Eberly on Q4 2020 Results - Earnings Call Transcript

HAUPPAUGE, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2020.

Chembio Diagnostics Reports Fourth Quarter and Full Year 2020 Financial Results

HAUPPAUGE, N.Y., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2020 after the close of trading on Thursday, March 11, 2021.

Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

HAUPPAUGE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company's Board of Directors.

Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors

Investors need to pay close attention to Chembio Diagnostics (CEMI) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Chembio Diagnostics (CEMI) Stock?

Chembio Diagnostics (CEMI) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Chembio Diagnostics (CEMI) Surges: Stock Moves 8.5% Higher

HAUPPAUGE, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. The contract will support the development and pursuit of U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for a rapid, multiplex DPP Respiratory Antigen Panel point-of-care test system using Chembio's proprietary DPP technology for the upcoming flu season.

Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System

In this article we will take a look at whether hedge funds think Chembio Diagnostics Inc (NASDAQ:CEMI) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks historically outperformed the market after adjusting for known risk factors.

Is Chembio Diagnostics Inc (CEMI) A Good Stock To Buy?

HAUPPAUGE, N.Y., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiary Chembio Diagnostics Brazil Ltda. has received regulatory approval from Agência Nacional de Vigilância Sanitária (ANVISA) to market the DPP SARS-CoV-2 Antigen test system in Brazil.

Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

Chembio Diagnostics, Inc. (CEMI) CEO Rick Eberly on Q3 2020 Results - Earnings Call Transcript

HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2020.

Chembio Diagnostics Reports Third Quarter 2020 Financial Results

HAUPPAUGE, N.Y., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter 2020 after the close of trading on Thursday, November 5, 2020.

Chembio Diagnostics to Report Third Quarter 2020 Financial Results on November 5, 2020

Rapid Test Provides Results in Only 20 Minutes Rapid Test Provides Results in Only 20 Minutes

Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System

First Rapid Test Approved in U.S. to Aid in Diagnosis of Both HIV and Syphilis from Single Patient Sample First Rapid Test Approved in U.S. to Aid in Diagnosis of Both HIV and Syphilis from Single Patient Sample

Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System

Investors need to pay close attention to Chembio (CEMI) stock based on the movements in the options market lately.

Implied Volatility Surging for Chembio (CEMI) Stock Options

New Antibody Test System Provides Results in 15 Minutes from Finger Stick, Venous Whole Blood, Plasma, or Serum Samples New Antibody Test System Provides Results in 15 Minutes from Finger Stick, Venous Whole Blood, Plasma, or Serum Samples

Chembio Submits EUA Application for New DPP SARS-CoV-2 IgM/IgG Test System

Los Angeles, California--(Newsfile Corp. - August 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnostics, Inc.

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Chembio Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Chembio Diagnostics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Chembio Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2020 - CEMI

Los Angeles, California--(Newsfile Corp. - August 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnostics, Inc.

DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Chembio Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 14, 2020) -  Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Chembio Diagnostics, Inc.

CEMI DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Chembio Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020

News for Chembio Diagnostics Stock (CEMI)